We previously described that imiquimod (TLR7‐L) treatment in melanoma‐bearing mouse models can reverse the tolerogenic activity of tumor‐infiltrating pDCs, triggering their cytotoxic functions and impeding tumor vascularisation.46 The gene discussed is TLR7; the disease is neoplasm.